Digital Tools in Lifestyle Medicine in Viet Nam: What Apps, Wearables and Remote Monitoring Can and Cannot Do
RESEARCH & IMPLEMENTATION


Digital Tools in Lifestyle Medicine in Viet Nam: What Apps, Wearables and Remote Monitoring Can and Cannot Do
Last reviewed: November 8, 2026
Smartwatches, fitness trackers and health applications have made it easier than ever to collect information about everyday life. People can monitor their steps, heart rate, sleep patterns and body weight without visiting a healthcare facility. Some devices can also generate notifications about potentially abnormal physiological findings.
For Lifestyle Medicine, this creates useful opportunities. Many of the behaviors that influence health take place between clinical appointments. Digital tools may help patients recognize patterns, review progress and discuss their experiences more meaningfully with healthcare professionals.
But a number displayed on a smartwatch is not automatically a clinically reliable measurement.
A device may estimate sleep duration without accurately identifying sleep disorders. A heart rhythm alert may identify a possible problem that requires assessment, but it can also be incorrect. A blood-pressure estimate may appear precise without meeting the requirements for clinical measurement.
There is another important distinction. A consumer wellness product, a regulated medical device and a healthcare service that uses remote monitoring are not the same thing.
Each may involve different expectations concerning performance, safety, professional responsibility and legal compliance.
For Viet Nam, responsible digital Lifestyle Medicine therefore requires more than encouraging people to use technology. It requires understanding what a device was designed to do, whether its performance has been adequately evaluated, how the information should be interpreted and who is responsible when the findings may affect clinical care.
The central question is not how much health data we can collect.
It is whether the information is sufficiently reliable, clinically useful and appropriately managed to support better decisions.
Where Digital Tools Can Contribute to Lifestyle Medicine
Lifestyle Medicine involves understanding and supporting behaviors that develop over time.
A clinical consultation provides only a limited view of these behaviors. A patient may describe being physically active but spend most working days sitting. Another may report poor sleep without being able to identify patterns associated with work schedules, stress or other factors.
Digital tools can help make these experiences more visible.
Activity trackers may provide feedback about movement throughout the day. Applications can support goal setting, reminders and self-monitoring. Connected devices may allow selected measurements to be reviewed between consultations.
These functions can contribute to behavior-change support when they are relevant to the patient's needs.
The Lifestyle Medicine Core Competencies: 2025 Update recognizes digital health, telehealth, clinical information systems and outcome monitoring as relevant professional capabilities.
The World Health Organization's 2023 classification of digital health interventions also distinguishes among different uses of technology, including health tracking, decision support, longitudinal health records and remote monitoring.
However, the presence of digital technology does not establish that an intervention is clinically effective.
The outcome depends on what the technology does, how accurately it performs, whether patients can use it and how it is incorporated into an appropriate healthcare process.
A step counter may support a discussion about physical activity.
It does not necessarily provide a reliable measure of total energy expenditure or establish that the person has achieved an appropriate level of physical fitness.
Likewise, a sleep application may encourage awareness of sleep habits without being capable of diagnosing a sleep disorder.
These distinctions should be clear before digital measurements are used in clinical decisions.
Consumer Wellness Technology Is Not the Same as a Medical Device
Many people assume that a product becomes a medical device simply because it measures something related to health.
The distinction is more complex.
Consumer wellness technologies generally focus on activities such as fitness tracking, lifestyle awareness, general health education or personal goal setting.
A step-counting application, for example, may be intended to encourage movement rather than diagnose or monitor a disease.
A medical device may have a different intended purpose.
Depending on its design and claims, a device or software function may be intended for diagnosis, disease monitoring, treatment, prevention or another regulated medical purpose.
The intended purpose is central to determining its regulatory status.
Importantly, the same physical product may contain different functions with different regulatory implications.
A smartwatch may provide ordinary activity tracking while also incorporating a software function intended to identify possible cardiac rhythm abnormalities.
The presence of a regulated function does not mean that every other measurement from that watch has been clinically validated or authorized for medical use.
The reverse is also true. A device sold as a consumer product should not be assumed suitable for clinical decisions simply because it displays health-related information.
Marketing language cannot replace proper assessment of the product's intended purpose and regulatory status.
For healthcare organizations, the practical distinction is between information used for general lifestyle awareness and information intended to support diagnosis, monitoring or treatment.
As the potential consequences of an incorrect measurement increase, so does the need for appropriate evidence, controls and professional oversight.
What Vietnamese Medical Device Regulation Requires
In Viet Nam, Decree No. 98/2021/NĐ-CP on Medical Device Management, as amended, provides the principal regulatory framework for medical devices.
The framework expressly includes software when it meets the applicable criteria and has an intended medical purpose.
Medical devices are classified according to risk into four categories: A, B, C and D.
These classifications reflect different levels of potential risk and are connected to applicable regulatory requirements.
The Decree has been amended by subsequent instruments, including Decree No. 07/2023/NĐ-CP and Decree No. 04/2025/NĐ-CP.
On March 6, 2026, the Ministry of Health issued Consolidated Document No. 08/VBHN-BYT, bringing together the relevant provisions of the medical-device management decree as amended.
A further development occurred on June 30, 2026, when the Ministry of Health issued Circular No. 24/2026/TT-BYT, effective July 1, 2026.
The Circular addresses risk determination and management measures for products classified as medical devices and amends selected provisions of Circular No. 05/2022/TT-BYT.
These requirements are relevant when a digital health product or software function falls within the definition of a medical device.
However, none of these instruments establishes that all smartwatches, fitness trackers or health applications are medical devices.
The applicable classification depends on the product's intended purpose, functions, claims and other relevant regulatory criteria.
Before incorporating a device into clinical care, a Vietnamese healthcare organization should determine whether it is legally marketed for the intended use and whether the relevant medical-device requirements have been satisfied.
This may involve checking the applicable declaration or circulation registration information, risk classification, authorized intended use and other product documentation.
The appropriate requirements can differ according to the device category and applicable transitional provisions.
Regulatory authorization in another country does not automatically establish authorization for the same medical-device use in Viet Nam.
A product described as cleared or authorized by the United States Food and Drug Administration, or bearing a European conformity marking, still requires consideration of the applicable Vietnamese requirements.
There is also an important distinction between regulatory status and clinical performance.
A device may be legally marketed for a particular intended use without being suitable for every population, clinical condition or treatment decision.
Healthcare organizations should therefore evaluate both regulatory compliance and the evidence supporting the specific use they intend to make of the device.
Measurement Accuracy Depends on What Is Being Measured
Wearable devices frequently display several measurements on the same screen.
This can create the impression that all the numbers have comparable accuracy.
They do not.
The reliability of a measurement can vary according to the sensor, algorithm, device model, software version, population, activity and environmental conditions.
Some measurements are based relatively directly on sensor signals. Others are estimates generated through mathematical models and proprietary algorithms.
For example, a smartwatch may use optical sensors to estimate heart rate. Its estimate of calories burned may then combine sensor information with assumptions about movement, body characteristics and metabolic activity.
The second number is not simply another direct physiological measurement.
A 2026 systematic review and meta-analysis by Lambe and colleagues examined the accuracy of Apple Watch measurements across 82 studies involving 14 health metrics.
The results showed that performance differed substantially across measurements.
Heart-rate measurement was relatively well supported, although meaningful variability remained. Accuracy for sleep and step counts was more moderate, while energy expenditure estimates showed inconsistent and sometimes substantial errors.
The findings should not be generalized to every smartwatch manufacturer, device generation or clinical application.
They do, however, illustrate why evaluating a product as a whole is insufficient.
The important question is whether the particular measurement is accurate enough for the particular decision being considered.
Step Counts and Activity Estimates Have Limitations
Step counts are among the most familiar wearable measurements.
They can provide useful feedback about movement and help people recognize daily patterns.
However, step-counting performance varies according to walking speed, movement patterns, where the device is worn and other factors.
Accuracy may be better during ordinary walking than during some forms of slow, irregular or assisted movement.
Activities such as cycling, resistance training or certain occupational tasks may not be adequately represented by step count.
For people with mobility limitations, a conventional step target may be inappropriate or fail to reflect meaningful physical activity.
Energy expenditure estimates are generally more uncertain.
Watches often calculate calories burned using combinations of movement data, heart rate and proprietary algorithms.
These estimates may be useful for broad personal feedback but should not automatically be treated as precise measurements for clinical nutrition prescriptions.
A person should not be encouraged to match food intake to a wearable's calorie estimate as though it were a laboratory measurement.
A July 2026 review in Sensors emphasized that smartwatch-derived metrics vary considerably in validity and that within-person trends may be more informative than precise numerical comparisons across devices.
For Lifestyle Medicine, the practical implication is to select a measure that fits the goal.
Step count may be helpful for supporting appropriate walking behavior.
It should not be mistaken for a comprehensive assessment of physical activity, fitness or energy expenditure.
Heart Rate, Sleep and Oxygen Measurements Require Context
Optical heart-rate monitoring has improved considerably, but it remains subject to measurement limitations.
Movement, device placement, contact with the skin, physiological characteristics and other conditions can affect signal quality.
Heart-rate estimates obtained during ordinary activities may not have the same accuracy as measurements obtained during certain forms of intensive or irregular movement.
This matters when the information is used to guide exercise intensity, investigate symptoms or evaluate treatment.
Sleep tracking introduces another difficulty.
A consumer device may estimate sleep duration or identify periods of movement and apparent rest.
However, the algorithms used to classify sleep stages are not equivalent to the clinical measurements obtained through appropriately performed sleep studies.
An estimate of poor sleep quality or reduced deep sleep should not automatically be interpreted as a diagnosis.
Similarly, a reassuring sleep score does not exclude obstructive sleep apnea, chronic insomnia or another clinically important problem.
The clinical relevance depends on symptoms, history and appropriate assessment.
Oxygen saturation measurements also require caution.
Even medical-purpose pulse oximeters have limitations.
The United States Food and Drug Administration has highlighted factors that can affect pulse oximetry accuracy, including circulation, skin pigmentation, skin temperature and other measurement conditions.
The agency has also raised concerns about accuracy differences across skin pigmentation.
Consumer devices may have different intended purposes and validation evidence from medical-purpose pulse oximeters.
A smartwatch oxygen reading should therefore not automatically be treated as equivalent to a clinically validated measurement.
When a patient has significant breathlessness or other concerning symptoms, appropriate clinical evaluation is necessary regardless of whether a wearable displays a reassuring number.
Blood Pressure: A Particularly Important Safety Distinction
Blood-pressure monitoring is one area where measurement reliability has direct implications for diagnosis and treatment.
Patients with hypertension may use connected home monitors to record readings and share them with healthcare professionals.
When an appropriate device and technique are used, home blood-pressure monitoring can provide valuable information.
However, not every device displaying a blood-pressure estimate is suitable for clinical use.
Some wearables estimate blood pressure without an inflatable cuff.
These technologies may use optical signals, pulse-wave characteristics or other algorithms, sometimes requiring calibration against conventional measurements.
Their performance has varied across studies and devices.
The 2025 American Heart Association and American College of Cardiology hypertension guideline explicitly states that cuffless blood-pressure devices are not recommended for diagnosing or managing high blood pressure in adults.
The American Heart Association recommends appropriately validated automatic upper-arm cuff devices for routine home monitoring, with a correctly sized cuff and suitable measurement technique.
In September 2025, the United States Food and Drug Administration also issued a warning concerning unauthorized devices claiming to measure or estimate blood pressure.
The concern is not merely technical.
An incorrectly low reading may delay recognition or treatment of hypertension. An incorrectly high reading may lead to unnecessary concern or inappropriate treatment changes.
For healthcare professionals in Viet Nam, the practical lesson is to verify the intended use and validation of a blood-pressure device before relying on it for clinical decisions.
A smartwatch's blood-pressure function should not automatically replace an appropriately validated clinical or home blood-pressure monitor.
Patients should not independently adjust antihypertensive medication on the basis of readings from a consumer wearable.
Glucose Measurements: Not Every Smartwatch Can Measure Blood Sugar
Another important example concerns glucose monitoring.
Some commercially promoted smartwatches or rings claim to estimate blood glucose without a sensor that penetrates the skin.
These claims require particular scrutiny.
In February 2024, the United States Food and Drug Administration warned against smartwatches and smart rings claiming to measure blood glucose independently without piercing the skin.
The agency stated that it had not authorized, cleared or approved a smartwatch or smart ring intended to measure or estimate blood glucose on its own.
This warning should be distinguished from the use of a smartwatch to display information transmitted by a separate, appropriately authorized continuous glucose monitoring system.
In that situation, the watch may function as a display or interface rather than independently measuring glucose.
The difference matters because inaccurate glucose readings can lead to serious treatment errors.
For patients taking insulin or other medicines associated with hypoglycemia, incorrect measurements may contribute to inappropriate dosing decisions.
The regulatory status of a particular product and the evidence supporting its performance should be verified for the market and use concerned.
Patients should not rely on unsupported noninvasive glucose claims or make medication changes based on measurements that have not been adequately validated for clinical use.
A Health Alert Is Not a Diagnosis
Wearables increasingly generate alerts concerning heart rhythm, heart rate or other physiological patterns.
These alerts may be useful when they draw attention to a previously unrecognized problem.
However, they can also be incorrect.
A heart rhythm notification may be triggered by measurement artifacts, irregular beats that do not represent the suspected disorder or other limitations of the device and algorithm.
The likelihood that an alert represents a true clinical condition also depends on the population being monitored.
For a condition that is uncommon in a particular population, even a test with relatively good sensitivity and specificity can generate a substantial proportion of false-positive alerts.
This is why screening performance cannot be assessed using sensitivity and specificity alone.
The clinical interpretation also depends on the underlying probability of disease, positive predictive value, intended population and consequences of an incorrect result.
The United States Food and Drug Administration has recognized these concerns in its post-market evaluation of smartwatch cardiovascular notifications.
The agency's research program examines how notifications affect subsequent clinical assessments and the possibility that false alerts may lead to unnecessary investigations or treatment.
False-negative findings deserve equal attention.
A wearable that does not generate an alert cannot reliably exclude every relevant medical condition.
Some abnormalities occur intermittently. Others may not be detected because the device is not being worn, the signal is inadequate or the algorithm is not designed to recognize the particular problem.
A patient with concerning symptoms should not delay medical assessment because no alert appeared.
Likewise, an alert suggesting a possible arrhythmia should not automatically lead to medication initiation, including anticoagulation, without appropriate clinical assessment and diagnostic confirmation.
The correct response depends on symptoms, urgency, the device's intended use and professional judgment.
A useful alert identifies a reason to assess. It does not automatically establish what diagnosis or treatment is required.
False Alerts Can Also Create Harm
Digital health discussions often focus on the benefits of detecting problems earlier.
However, alerts may have unintended consequences.
A false notification can cause anxiety, repeated self-monitoring, unnecessary appointments or investigations.
Some patients may become preoccupied with fluctuations in heart rate, sleep scores or other measurements that have limited clinical meaning.
Healthcare professionals may also experience alert fatigue when large numbers of notifications require review but only a small proportion lead to meaningful clinical action.
These problems are particularly important when a digital program is expanded to a large population.
More alerts do not necessarily mean better monitoring.
A responsible service should establish which findings are clinically relevant, how alerts are prioritized and which require professional review.
The consequences of missed alerts also need to be considered.
If a system is presented as monitoring a patient's condition, users may assume that significant abnormalities will always be detected and acted upon.
That assumption can be dangerous.
Patients should understand whether the device is intended for general awareness, self-monitoring or an organized clinical monitoring service.
They should also know whether information is being actively reviewed by a healthcare team and what to do when symptoms require urgent attention.
Regulatory Authorization and Clinical Validation Are Different
When evaluating a digital health product, healthcare organizations should distinguish three related questions.
The first is whether the product is legally permitted to be marketed or used for its stated purpose under the applicable regulatory framework.
The second is whether its performance has been adequately validated for the specific measurement, population and conditions in which it will be used.
The third is whether incorporating the product into care improves meaningful clinical or patient outcomes.
These are different questions.
A device may satisfy relevant regulatory requirements while still having known limitations.
A technically accurate measurement may provide little clinical benefit if it does not influence care.
An application may improve engagement without demonstrating better long-term disease outcomes.
For wearable measurements, validation should be specific.
Relevant questions include whether the exact device model and software version were studied, which reference measurement was used and whether the study included people similar to the intended users.
Performance may differ according to age, skin characteristics, movement patterns, underlying disease and other factors.
Healthcare organizations should also consider whether software updates could change the algorithms used to generate measurements.
A validation study conducted on an earlier device or software version may not establish the performance of every subsequent version.
Where a measurement may influence clinical treatment, the evidence should be strong enough for that intended use.
A consumer product's popularity, price or brand reputation cannot substitute for this assessment.
What Does the Evidence Say About Digital Lifestyle Interventions?
Digital interventions can support selected health behaviors, but their effects vary.
A 2025 systematic review and meta-analysis by Lee and Park examined 18 randomized controlled trials of stand-alone digital behavior-change interventions.
The authors found improvements in physical activity and selected body-related measures, although the certainty of evidence varied.
A 2026 meta-analysis involving 19 randomized trials and 3,556 adults with overweight or obesity also reported improvements in weight-related and dietary outcomes from stand-alone digital lifestyle interventions.
However, differences between studies were substantial, and prediction intervals suggested that benefits may not occur in every setting.
Evidence concerning wearables also requires careful interpretation.
A 2026 umbrella review published in Physiological Reviews identified 39 systematic reviews covering 98 original studies.
Interventions incorporating wrist-worn wearables generally improved physical activity.
However, evidence for broader outcomes, including cardiometabolic risk markers, quality of life and some psychological or pain-related outcomes, was less consistent.
Most of the original clinical trials evaluated wearables as part of more complex interventions, not simply as devices given to participants without additional support.
This distinction matters.
A positive outcome may depend on counseling, feedback, goal setting, professional contact or other elements of the program.
The presence of a smartwatch does not establish which component produced the benefit.
For Lifestyle Medicine, the most defensible conclusion is that digital tools may support some behaviors and aspects of care when appropriately selected and implemented.
They should not be described as universally effective or as replacements for evidence-based clinical assessment and treatment.
Remote Monitoring Needs a Responsible Healthcare Professional
Remote monitoring goes beyond personal tracking when measurements become part of an organized healthcare service.
A patient with hypertension may submit home blood-pressure readings for clinical review.
Someone with diabetes may use an appropriate glucose monitoring system connected to their treatment plan.
A patient undergoing rehabilitation may share selected activity or functional information with an authorized care team.
In each situation, the technology can extend the availability of information beyond the clinic.
However, remote monitoring requires an operational response.
The healthcare organization needs to define which measurements will be reviewed, how frequently this will occur, who is responsible and what happens when an important abnormality appears.
It should also establish how information is documented and communicated.
Not every notification needs an immediate clinical response. But clinically significant findings require clear arrangements consistent with the service's actual capabilities.
A patient should not be told or led to believe that a monitoring platform provides continuous professional surveillance unless the organization genuinely offers that level of service.
Likewise, a device should not be presented as an emergency response system when it has not been designed or supported for that purpose.
The responsibility for diagnosis, treatment and prescription decisions remains with appropriately authorized healthcare professionals.
Technology can support those decisions. It does not transfer professional accountability to a device or software vendor.
Remote Monitoring and Vietnamese Healthcare Law
Viet Nam's Law on Medical Examination and Treatment governs regulated clinical activities, including medical examination and treatment delivered remotely.
The current consolidated version is reflected in Consolidated Document No. 26/VBHN-VPQH dated February 26, 2026.
Decree No. 96/2023/NĐ-CP provides further implementing provisions.
Article 87 of the Decree establishes conditions and procedures concerning remote medical examination and treatment.
These include requirements involving eligible healthcare facilities, appropriate professional scope, qualified practitioners and suitable technological infrastructure.
The infrastructure must support secure transmission, display, processing and storage of data and meet applicable requirements concerning retention and backup.
The Decree also provides for notification and publication arrangements concerning facilities that satisfy the relevant conditions.
These requirements should not be interpreted to mean that every fitness application or consumer wearable constitutes remote medical examination and treatment.
The legal classification depends on the substance of the activity and how the service is provided.
A general educational reminder differs from a clinician diagnosing disease or changing treatment through a remote consultation.
However, where digital monitoring is used as part of regulated medical examination or treatment, the relevant healthcare requirements must be considered.
A technology provider or health coach does not independently acquire medical practice authority by participating in a remote-monitoring program.
The healthcare organization remains responsible for ensuring that professional activities are legally appropriate.
Personal Health Data Require Stronger Protection Than an Ordinary App Account
Wearable technology can generate detailed information about a person's daily life.
Depending on the product, this may include heart rate, physical activity, sleep patterns, weight, glucose, location, health conditions, medication use and other personal information.
Individual measurements may appear relatively harmless when viewed separately.
However, repeated measurements can reveal sensitive patterns about a person's health, routines and behavior.
Combining information from wearables, smartphones, health applications and medical records may also increase privacy risks.
Viet Nam's Law on Personal Data Protection No. 91/2025/QH15 took effect on January 1, 2026.
Decree No. 356/2025/NĐ-CP, effective on the same date, provides detailed requirements and implementation measures.
The Law contains specific provisions concerning health information and health-related applications.
Where consent is the applicable legal basis for processing personal data, consent must satisfy the relevant requirements concerning information, voluntariness and clear expression.
The law also provides for circumstances in which processing may take place without consent under specified legal conditions.
For digital Lifestyle Medicine services, the practical questions are therefore broader than whether a user has accepted a privacy policy.
Patients should understand what information is collected, why it is needed, who is involved in processing it and how it may be shared or used.
Healthcare organizations should determine the responsibilities of service providers, device manufacturers, application developers and other parties involved in data processing.
Not every physiological measurement is automatically biometric identification data under Vietnamese law.
The legal classification depends on the nature and purpose of the information. Identifiable health information, location data and data processed for biometric identification may trigger different requirements.
The applicable obligations should therefore be assessed according to the actual processing activities rather than assuming that every wearable data point falls into the same category.
Health Data Management and Cybersecurity Are Part of Patient Safety
In addition to personal-data protection requirements, Decree No. 102/2025/NĐ-CP on Health Data Management, effective July 1, 2025, provides a relevant framework for digital health data within its scope.
Healthcare organizations should understand how patient information is stored, accessed, processed and retained.
This becomes particularly important when data from consumer applications are imported into clinical records or shared with external service providers.
A device may transmit information through several systems before a clinician sees it.
The data may pass from the wearable to a smartphone, a manufacturer-operated cloud platform, another application and eventually a healthcare organization's information system.
Each transfer introduces questions about accuracy, security, responsibility and access.
Organizations should evaluate whether the data remain correctly associated with the patient, whether records can be altered or lost and whether inappropriate access is adequately prevented.
Where external vendors or international cloud services are involved, applicable requirements concerning contracts, personal-data processing and cross-border transfers must also be considered.
Depending on the circumstances, the personal-data framework may require data-processing impact assessments or cross-border transfer impact assessments.
Viet Nam also introduced Decree No. 330/2026/NĐ-CP, effective August 19, 2026, establishing administrative sanctions for violations involving cybersecurity and personal-data protection.
These developments reinforce the importance of appropriate compliance and information governance.
However, the objective is not merely to avoid regulatory penalties.
Incorrect, missing or improperly disclosed health information can affect patient safety, trust and continuity of care.
Data protection and clinical quality should therefore be considered together.
A Wearable Should Not Become a Tool for Judging Patients
Lifestyle Medicine emphasizes patient-centered care and sustainable behavior change.
Digital monitoring should support these principles.
For some people, step counts and activity reminders are motivating.
For others, constant monitoring can become stressful or burdensome.
A person may become concerned about a sleep score despite feeling well. Another may feel discouraged after a day with fewer steps because of illness, work or caregiving responsibilities.
Data should not be used to label patients as successful or unsuccessful based on rigid numerical targets.
Health behavior occurs within social, economic and personal circumstances.
A person working irregular shifts may have very different opportunities for sleep and physical activity from someone with flexible working hours.
A patient experiencing pain or mobility limitations may require a different activity goal.
Digital tools should help healthcare professionals understand these circumstances, not ignore them.
The most useful application may be one that makes a conversation more informed rather than one that produces more frequent reminders.
The option not to use continuous tracking should also be considered when it is unnecessary or creates additional burden.
Digital Health Can Increase Inequality
Digital technology is often described as scalable because applications can reach large numbers of users.
However, technical availability is not the same as practical accessibility.
People may face barriers related to device cost, internet access, language, digital literacy, disability or age.
A program designed around smartphone applications may work well for digitally confident urban adults but be less suitable for some older people or those with limited resources.
The cost of devices, subscriptions and mobile data can also create financial barriers.
For Viet Nam, digital Lifestyle Medicine should therefore be evaluated in relation to the populations it is intended to serve.
An intervention that improves care for one group may unintentionally widen disparities if others cannot participate.
Healthcare organizations should consider appropriate alternatives for patients who cannot or do not wish to use a wearable or application.
A non-digital pathway may remain important for equitable care.
The goal is improved access and better health, not maximizing digital participation for its own sake.
What Should Healthcare Organizations Check Before Adopting a Device?
A useful evaluation begins with the clinical or behavioral problem.
The organization should identify why a device is being considered and what decision its information is expected to support.
If the purpose is helping patients notice changes in daily walking, a relatively simple activity tracker may be sufficient.
If the purpose is diagnosing or managing hypertension, a suitably validated blood-pressure device is necessary.
If the purpose is investigating a potentially important cardiac rhythm abnormality, the relevant clinical evidence, professional assessment and diagnostic pathway become central.
The next question concerns the product itself.
What is the manufacturer's stated intended purpose? Has the relevant function been evaluated for that use? What is the regulatory status of the product in Viet Nam?
Where applicable, the organization should review appropriate medical-device documentation and circulation status.
It should then examine measurement performance.
Has the exact device model or software function been validated against an appropriate reference? Were relevant populations and conditions included? Are there known limitations involving movement, skin characteristics or other factors?
The organization should also understand how software updates may affect performance.
If the device generates alerts, the intended response must be defined.
Who reviews them? Which findings require further assessment? What is communicated to patients? What happens when the service is unavailable?
The data-processing arrangement also requires assessment.
Healthcare organizations need to understand which parties receive information, where it is stored and which contractual, privacy and security requirements apply.
Finally, they should consider cost, staff workload, patient acceptance and available non-digital alternatives.
These questions provide a practical review structure. They do not replace formal medical-device classification, procurement requirements or clinical validation processes applicable to a specific product.
The Role of Healthcare Professionals Cannot Be Automated Away
Digital tools may support clinical work, but they do not eliminate the need for professional judgment.
A clinician interpreting wearable data should understand what the device measures, what it estimates and how reliable the information is for the intended decision.
An abnormal result may require confirmation with an appropriate clinical method.
A reassuring result may still be insufficient when the patient's symptoms suggest a significant problem.
Healthcare professionals also need to consider whether the device's findings are consistent with the person's history, clinical condition and other available evidence.
Where monitoring forms part of clinical care, the relevant team should have clear responsibilities for reviewing information, communicating with patients and responding to important findings.
These responsibilities must remain within legally authorized professional scopes.
An app cannot independently authorize a health coach to diagnose disease.
A smartwatch alert does not authorize a non-prescribing professional to initiate medication.
A digital platform does not change the qualifications required to provide regulated medical examination or treatment in Viet Nam.
Technology may change how information is collected and communicated.
It does not automatically change who is responsible for clinical decisions.
What Should Digital Lifestyle Medicine Measure?
When organizations introduce apps or wearables, there is a temptation to measure success through digital activity.
The number of downloads, device users, uploaded measurements or app interactions may be useful operational information.
However, these indicators do not establish clinical value on their own.
The more important question is whether the technology supports the intended outcome.
For an activity program, this may involve meaningful changes in physical activity and relevant patient-reported outcomes.
For home blood-pressure monitoring, it may involve appropriate measurement, timely clinical review and improved management of hypertension.
For remote follow-up, it may involve better continuity, fewer missed reviews and more reliable communication.
Safety should also be evaluated.
A program generating many false alerts may create substantial workload without corresponding clinical benefit.
A system with poor data quality may produce misleading conclusions.
Researchers and healthcare organizations should also examine patient burden, affordability and equity.
The purpose is not to collect the largest dataset.
It is to collect information that can be interpreted correctly and used for a defined purpose.
Broader evaluation of clinical and implementation indicators is addressed separately in VLMA's article Measuring Lifestyle Medicine in Vietnamese Healthcare: What Outcomes and Quality Indicators Should We Track?
The Responsible Role of VLMA
The Vietnam Lifestyle Medicine Alliance (VLMA) can contribute to professional understanding of digital tools through evidence-based education, scientific knowledge exchange and critical assessment of emerging technologies.
Wearables and health applications are relevant to Lifestyle Medicine because they may support assessment, behavior change and continuity of care.
However, VLMA should not promote a particular product as clinically effective solely because it is popular or technically sophisticated.
Educational discussion should distinguish between consumer wellness applications, regulated medical devices and healthcare services that use digital monitoring.
It should also explain the limitations of measurements, the possibility of false alerts and the importance of professional responsibility.
Where a product is discussed, its intended purpose, validation evidence and regulatory status should be considered.
VLMA's scientific and educational role does not independently authorize medical-device registration, regulated clinical services or the use of personal health information outside applicable legal requirements.
A responsible contribution is to help professionals understand the evidence and limitations before adopting technology in care.
Technology Should Improve Care, Not Be Mistaken for Care
Apps, wearables and remote monitoring can support Lifestyle Medicine in meaningful ways.
They can help patients observe behaviors, make goals more concrete and provide information that is not available during a short consultation.
In selected healthcare settings, appropriately validated devices and well-designed monitoring systems may also strengthen continuity and clinical decision-making.
However, more information does not automatically mean better decisions.
An inaccurate measurement may create false reassurance or unnecessary concern. An alert may identify a reason for further assessment without establishing a diagnosis. A device may be legally marketed for one intended use but unsuitable for a different clinical purpose.
Personal health information also creates responsibilities involving privacy, security and appropriate use.
For Viet Nam, the most useful direction is therefore not to encourage the indiscriminate adoption of digital health technologies.
It is to select tools according to their intended purpose, understand their limitations, verify relevant regulatory requirements and integrate clinically important information into care delivered by appropriately qualified professionals.
A wearable may help someone understand their behavior. A medical device may provide information for a defined clinical purpose. A healthcare professional remains responsible for determining what that information means for the patient.
That distinction is fundamental to responsible digital Lifestyle Medicine.
Technology should make care more informed, accessible and continuous where it can demonstrate value.
It should never be mistaken for clinical care itself.
References and Further Reading
Rea BL, Cheema S, Lanza S, et al. Lifestyle Medicine Core Competencies: 2025 Update. American Journal of Lifestyle Medicine. 2026;20(3):443–451. doi:10.1177/15598276251379821.
World Health Organization. Classification of Digital Interventions, Services and Applications in Health: A Shared Language to Describe the Uses of Digital Technology for Health. 2nd edition. Geneva: World Health Organization; 2023.
Lee SA, Park JH. Systematic Review and Meta-analysis of Standalone Digital Behavior Change Interventions on Physical Activity. npj Digital Medicine. 2025;8:436. doi:10.1038/s41746-025-01827-4.
Lee SA, Park JH. Effects of Stand-Alone Digital Lifestyle Interventions on Weight-Related Outcomes in Adults With Overweight or Obesity: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Medical Internet Research. 2026;28. doi:10.2196/81070.
Glisic M, Llane A, Stojic S, et al. An Umbrella Review of Systematic Reviews of the Impact of Wrist-Worn Wearables on Health Outcomes. Physiological Reviews. 2026;106(2):935–969. doi:10.1152/physrev.00049.2024.
Lambe R, Baldwin M, O'Grady B, et al. The Accuracy of Apple Watch Measurements: A Living Systematic Review and Meta-analysis. npj Digital Medicine. 2026;9:63. doi:10.1038/s41746-025-02238-1.
Lepley AS, Davis F, Melvin AC, Zhao ZY. Consumer Smartwatch Technology in Health and Performance Research: Validity, Limitations, and Real-World Applications. Sensors. 2026;26(14):4486. doi:10.3390/s26144486.
Jones DW, Ferdinand KC, Taler SJ, et al. 2025 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Circulation. 2025;152(11). doi:10.1161/CIR.0000000000001356.
American Heart Association. Home Blood Pressure Monitoring. Patient and professional information.
United States Food and Drug Administration. Post-Market Evaluation of Smartwatch Cardiovascular Notifications. Regulatory science research program.
United States Food and Drug Administration. Do Not Use Smartwatches or Smart Rings to Measure Blood Glucose Levels: FDA Safety Communication. February 21, 2024.
United States Food and Drug Administration. Do Not Use Unauthorized Devices for Measuring Blood Pressure: FDA Safety Communication. September 16, 2025.
United States Food and Drug Administration. Pulse Oximeter Basics. Consumer and professional information concerning performance limitations.
Government of Viet Nam. Decree No. 98/2021/NĐ-CP on Medical Device Management. November 8, 2021, as amended.
Government of Viet Nam. Decree No. 04/2025/NĐ-CP Amending Selected Provisions of Decree No. 98/2021/NĐ-CP on Medical Device Management. January 1, 2025.
Ministry of Health of Viet Nam. Consolidated Document No. 08/VBHN-BYT on Medical Device Management. March 6, 2026.
Ministry of Health of Viet Nam. Circular No. 24/2026/TT-BYT on Risk Determination and Management Measures for Medical Devices and Amendments to Circular No. 05/2022/TT-BYT. June 30, 2026; effective July 1, 2026.
Office of the National Assembly of Viet Nam. Consolidated Document No. 26/VBHN-VPQH, Law on Medical Examination and Treatment. February 26, 2026.
Government of Viet Nam. Decree No. 96/2023/NĐ-CP Detailing Selected Provisions of the Law on Medical Examination and Treatment. December 30, 2023.
National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15. June 26, 2025; effective January 1, 2026.
Government of Viet Nam. Decree No. 356/2025/NĐ-CP Detailing Selected Provisions and Implementation Measures of the Law on Personal Data Protection. December 31, 2025; effective January 1, 2026.
Government of Viet Nam. Decree No. 102/2025/NĐ-CP on Health Data Management. May 13, 2025; effective July 1, 2025.
Government of Viet Nam. Decree No. 330/2026/NĐ-CP on Administrative Penalties for Violations in Cybersecurity and Personal Data Protection. August 19, 2026; effective August 19, 2026.
Professional, Technical and Regulatory Note
This article is intended for professional education, scientific knowledge exchange and general information. It does not constitute individualized medical advice, a Vietnamese national clinical guideline, a medical-device regulatory determination, a product endorsement or an authoritative legal opinion.
The regulatory classification of a specific wearable, application, software function or connected device depends on its intended purpose, claims, functionality and applicable law. The classification, circulation status and legal authorization of individual products must be verified through the relevant regulatory processes.
Regulatory authorization does not guarantee suitability for every clinical use, and consumer wellness measurements should not automatically be used for diagnosis or treatment decisions. Clinically important findings may require confirmation through appropriate medical assessment and validated methods.
Patients should not initiate, stop, reduce or otherwise change prescribed medication solely on the basis of wearable measurements or automated notifications. Serious or worsening symptoms require appropriate medical evaluation regardless of the presence or absence of a device alert.
Healthcare services involving regulated medical examination, treatment or remote clinical monitoring must comply with applicable Vietnamese professional licensing, healthcare facility and clinical governance requirements.
The collection, storage, transfer and processing of identifiable health information must comply with applicable personal-data protection, health-data management, confidentiality and cybersecurity requirements.
The Vietnam Lifestyle Medicine Alliance is a physician-led professional platform supporting evidence-based Lifestyle Medicine through education, scientific knowledge exchange and responsible implementation. VLMA does not independently determine the regulatory status of medical devices, issue device marketing authorizations or provide regulated clinical monitoring and treatment services.
International scientific publications, professional recommendations and foreign regulatory communications are cited for educational purposes. They do not automatically establish Vietnamese regulatory requirements or authorization for a particular product or service.
Vietnam Lifestyle Medicine Alliance
Evidence-Based Lifestyle Medicine for Viet Nam.
Contact
contact@vlma.org
Saigon Paragon Building, No. 3 Nguyen Luong Bang Street, Tan My Ward, HCMC
+84 909 228 476
+84 84 9999 911
© 2025 - 2026. Vietnam Lifestyle Medicine Alliance. All rights reserved.
A physician-led professional platform advancing Lifestyle Medicine through education, collaboration, research, and responsible implementation.
VLMA is operated by Vietnam Lifestyle Medicine Alliance Company Limited, Enterprise Registration Number 0318902666.
VLMA is a Sister Organization of the Lifestyle Medicine Global Alliance and a Member Organization of the Planetary Health Alliance.
VLMA is not a medical service provider and does not issue medical licenses or IBLM certification.
